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Abstract
The five-star quality rating of Medicare Advantage Prescription Drug Plans had no direct impact on same-year
enrollment. But after the introduction of a bonus payment for highly-rated plans, which had to be invested in
additional benefits and /or reducing premiums, subsequent year enrollment in these plans increased.
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KEY FINDINGS: The five-star quality rating of Medicare Advantage Prescription Drug Plans had no direct impact on 
same-year enrollment. But after the introduction of a bonus payment for highly-rated plans, which had to be invested in 
additional benefits and /or reducing premiums, subsequent year enrollment in these plans increased. 
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Does an increase in a plan’s star rating have a direct impact 
on concurrent year plan enrollment? What’s the indirect 
impact (via bonus payments) of star ratings on subsequent 
year plan enrollment?
THE FINDINGS
Before the introduction of QBPs, an increase in a plan’s star 
rating had little effect on the plan’s enrollment, both in the 
concurrent and subsequent year. After the introduction of the 
bonus payment in 2012, an increase in a star rating resulted 
in an increase in enrollment, but only in the subsequent 
year. This was likely due to the reinvestment of QBPs to 
provide lower premiums and/or additional member benefits 
in the following year. There was still no direct impact on 
concurrent year enrollment.
THE QUESTION
To help beneficiaries make more informed enrollment 
decisions about Medicare Advantage Prescription Drug 
Plans (MAPDs), the Centers for Medicare & Medicaid 
Services (CMS) introduced a five-star rating system in 2007, 
and publishes these quality ratings annually. Initial reports 
on the influence of star ratings on plan enrollment have been 
mixed. In 2012, CMS also began awarding quality bonus 
payments (QBPs) to plans with three or more stars. The 
QBPs had to be reinvested to improve plan benefits and/or 
reduce premiums in the subsequent year.
In PLOS ONE, LDI Senior Fellows Pengxiang Li and Jalpa 
Doshi examine the impact of the MAPD star ratings before 
and after 2012, when they became tied to bonus payments. 
Hypothesized Direct and Indirect Relationships Between MAPD Contract Star Ratings and Enrollment.
Source: PLOS ONE, May 5, 2016; DOI:10.1371/journal.pone.0154357.s002
were not eligible for the QBPs. The authors compared the 
effects of star ratings in the pre-QBP period and the post-
QBP period. The analysis controlled for the type of plan, 
how long it had been part of the program, and the kind of 
beneficiaries that each plan served. Enrollment data were 
based on January enrollment. 
Li P, Doshi JA. Impact of Medicare Advantage Prescription Drug Plan 
Star Ratings on Enrollment Before and After Implementation of Quality-
Related Bonus Payments in 2012. DOI:10.1371/journal.pone.0154357.
s002. PLOS ONE, May 2016.
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THE IMPLICATIONS
This is the first longitudinal study to examine the impact 
of CMS star ratings on MAPD enrollment, and how QBPs 
affected that impact. The plans that receive a QBP are required 
to improve member benefits or to reduce premiums, which 
other research has suggested is an important determinant 
of a consumer’s plan selection. This reinvestment of the 
bonus, and what it likely did to attract consumers, meant a 
significant indirect impact of the star rating system. 
The authors comment: 
Although star ratings do not seem to be serving 
their intended function in regard to directly aiding 
plan selection, the associated financial incentives 
have increased their utility. It is notable that an 
increase in a contract’s star rating led to a significant 
increase in enrollment in the subsequent year. These 
lagged effects may be due to features of the rating 
program’s incentive system. 
One limitation of the study was the unavailability of other 
information that may be relevant to enrollees’ decision-
making, such as plan reputation, specific benefits, and 
volume or effectiveness of marketing efforts. 
THE STUDY
Using a longitudinal design, the authors analyzed 3,866 
MAPD program contract-years using primarily 2009 to 2015 
CMS Part C and Part D Performance Data and Medicare 
Advantage/Part D Contract and Enrollment Data. The data 
were divided into a pre-QBP period from 2009-2011 and a 
post-QBP period from 2012-2015. Stand-alone prescription 
drug plans served as an external comparison group as they
